Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Objective: To improve quality-of-life and health care delivery to patients receiving ureteral
stents.
Specific Aims: Evaluate the feasibility, practicality, and qualitative outcomes of utilizing
intra-nasal ketorolac in patients with indwelling ureteral stents (Phase I), followed by a
randomized trial comparing two non-steroidal anti-inflammatory drugs, intra-nasal Ketorolac
versus oral Diclofenac.
Hypotheses: Due to its favorable pharmacokinetics in relieving acute pain, investigators
expect improved pain scores and a lower rate of unplanned clinical encounters in patients
receiving intra-nasal ketorolac compared to those taking oral diclofenac following
ureteroscopic surgery for urolithiasis.
Study Rationale: Following ureteroscopic management of urolithiasis, patient with indwelling
ureter stents have higher levels of discomfort compared to those without a ureter stent.
Prior studies showed that intramuscular Ketorolac at time of ureter stent removal decreased
the incidence of unplanned clinical encounters. Furthermore, onset of analgesic effect by
intra-nasal ketorolac is faster than its oral form, and similar its intramuscular and
intravenous counterparts.